Abnova announced on February 3 that its established RNA technology platform is now positioned to support urgent vaccine R&D for the Nipah Virus (NiV), which has seen recent outbreaks in India with case fatality rates ranging from 40% to 75%.

• Platform Versatility: Unlike traditional vaccine manufacturing, Abnova's RNA platform offers rapid sequence design and standardized manufacturing. The platform covers the full spectrum from sequence design and process development to large-scale production.
• Vertical Integration: Abnova provides not only the RNA synthesis and purification technology but also the critical reagents required for production. This is paired with their proprietary automated synthesis and purification equipment, which ensures process reproducibility and capacity flexibility.
• Readiness: Leveraging experience gained during the COVID-19 pandemic, Abnova's platform is currently "battle-ready" to provide R&D and process support to research institutions and industry partners focusing on high-pathogenicity emerging viruses.

Resource: 亞諾法RNA平台 瞄準立百病毒疫苗研發